These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

517 related items for PubMed ID: 22773741

  • 1. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects.
    Chandorkar G, Huntington JA, Gotfried MH, Rodvold KA, Umeh O.
    J Antimicrob Chemother; 2012 Oct; 67(10):2463-9. PubMed ID: 22773741
    [Abstract] [Full Text] [Related]

  • 2. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.
    Xiao AJ, Miller BW, Huntington JA, Nicolau DP.
    J Clin Pharmacol; 2016 Jan; 56(1):56-66. PubMed ID: 26096377
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics and Tissue Penetration of Ceftolozane-Tazobactam in Diabetic Patients with Lower Limb Infections and Healthy Adult Volunteers.
    Monogue ML, Stainton SM, Baummer-Carr A, Shepard AK, Nugent JF, Kuti JL, Nicolau DP.
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893779
    [Abstract] [Full Text] [Related]

  • 5. Population Pharmacokinetic Analysis for Plasma and Epithelial Lining Fluid Ceftolozane/Tazobactam Concentrations in Patients With Ventilated Nosocomial Pneumonia.
    Zhang Z, Patel YT, Fiedler-Kelly J, Feng HP, Bruno CJ, Gao W.
    J Clin Pharmacol; 2021 Feb; 61(2):254-268. PubMed ID: 32949031
    [Abstract] [Full Text] [Related]

  • 6. Is One Sample Enough? β-Lactam Target Attainment and Penetration into Epithelial Lining Fluid Based on Multiple Bronchoalveolar Lavage Sampling Time Points in a Swine Pneumonia Model.
    Motos A, Kuti JL, Li Bassi G, Torres A, Nicolau DP.
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30509937
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration.
    Varghese JM, Jarrett P, Boots RJ, Kirkpatrick CM, Lipman J, Roberts JA.
    Int J Antimicrob Agents; 2014 Apr; 43(4):343-8. PubMed ID: 24612982
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.
    Butterfield JM, Lodise TP, Beegle S, Rosen J, Farkas J, Pai MP.
    J Antimicrob Chemother; 2014 Jan; 69(1):176-9. PubMed ID: 23869050
    [Abstract] [Full Text] [Related]

  • 9. Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects.
    Conte JE, Golden JA, McIver M, Zurlinden E.
    Int J Antimicrob Agents; 2006 Aug; 28(2):114-21. PubMed ID: 16837169
    [Abstract] [Full Text] [Related]

  • 10. Plasma and epithelial lining fluid pharmacokinetics of ceftolozane and tazobactam alone and in combination in mice.
    Melchers MJ, Mavridou E, Seyedmousavi S, van Mil AC, Lagarde C, Mouton JW.
    Antimicrob Agents Chemother; 2015 Aug; 59(6):3373-6. PubMed ID: 25824214
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK.
    Prabhu V, Foo J, Ahir H, Sarpong E, Merchant S.
    J Med Econ; 2017 Aug; 20(8):840-849. PubMed ID: 28532194
    [Abstract] [Full Text] [Related]

  • 12. Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia.
    Caro L, Nicolau DP, De Waele JJ, Kuti JL, Larson KB, Gadzicki E, Yu B, Zeng Z, Adedoyin A, Rhee EG.
    J Antimicrob Chemother; 2020 Jun 01; 75(6):1546-1553. PubMed ID: 32211756
    [Abstract] [Full Text] [Related]

  • 13. Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia.
    Boselli E, Breilh D, Cannesson M, Xuereb F, Rimmelé T, Chassard D, Saux MC, Allaouchiche B.
    Intensive Care Med; 2004 May 01; 30(5):976-9. PubMed ID: 15057512
    [Abstract] [Full Text] [Related]

  • 14. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
    Shea KM, Cheatham SC, Smith DW, Wack MF, Sowinski KM, Kays MB.
    Ann Pharmacother; 2009 Nov 01; 43(11):1747-54. PubMed ID: 19809009
    [Abstract] [Full Text] [Related]

  • 15. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?
    Roberts JA, Roberts MS, Robertson TA, Dalley AJ, Lipman J.
    Crit Care Med; 2009 Mar 01; 37(3):926-33. PubMed ID: 19237898
    [Abstract] [Full Text] [Related]

  • 16. Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L.
    Natesan S, Pai MP, Lodise TP.
    J Antimicrob Chemother; 2017 Oct 01; 72(10):2813-2816. PubMed ID: 29091209
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion.
    Buck C, Bertram N, Ackermann T, Sauerbruch T, Derendorf H, Paar WD.
    Int J Antimicrob Agents; 2005 Jan 01; 25(1):62-7. PubMed ID: 15620828
    [Abstract] [Full Text] [Related]

  • 18. Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem.
    Conte JE, Golden JA, Kelley MG, Zurlinden E.
    Int J Antimicrob Agents; 2005 Dec 01; 26(6):449-56. PubMed ID: 16280244
    [Abstract] [Full Text] [Related]

  • 19. Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients.
    Cheatham SC, Fleming MR, Healy DP, Chung CE, Shea KM, Humphrey ML, Kays MB.
    Int J Antimicrob Agents; 2013 Jan 01; 41(1):52-6. PubMed ID: 23228881
    [Abstract] [Full Text] [Related]

  • 20. Piperacillin-tazobactam pharmacokinetics in patients with intraabdominal infections.
    Jhee SS, Kern JW, Burm JP, Yellin AE, Gill MA.
    Pharmacotherapy; 1995 Jan 01; 15(4):472-8. PubMed ID: 7479200
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.